MYRICX BIO

Owners

Goods & Services

Scientific and biomedical research; scientific and biomedical research in the field of human diseases; scientific and biomedical research in the field of proliferative human diseases; scientific and biomedical research in the field of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging; development and testing of pharmaceuticals and biotechnological preparations; scientific and technological research, development and testing of pharmaceuticals and biotechnological preparations, including scientific and technological research for their commercialisation; development and testing of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of human diseases; development and testing of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of humandiseases, and scientific and technological research supporting their commercialisation; development and testing of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of proliferative human diseases; development and testing of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of proliferative human diseases, and scientific and technological research supporting their commercialisation; development and testing of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging; development and testing of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence, and diseases of aging, and scientific and technological research supporting their commercialisation; pharmaceutical product development and testing of antibody drug conjugates (ADCs) and Nmyristoyltransferases (NMT) inhibitors; pharmaceutical product development and testing of antibody-drug conjugates (ADCs) and N-myristoyltransferase (NMT) inhibitors, and scientific and technological research supporting their commercialisation; consultancy, advisory and information services relating to the aforesaid services

New product commercialisation services of pharmaceuticals and biotechnological preparations; new product commercialisation services of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of human diseases; new product commercialisation services of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of proliferative human diseases; new product commercialisation services of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging; new product commercialisation services of antibody drug conjugates (ADCs) and N-myristoyltransferases (NMT) inhibitors; consultancy, advisory and information services relating to the aforesaid services

Pharmaceutical and biotechnological preparations for human diseases, namely, cancer, fibrosis, inflammation, senescence, and diseases of aging; pharmaceutical and biotechnological preparations for the diagnosis and treatment of human diseases, namely, cancer, fibrosis, inflammation, senescence, and diseases of aging; pharmaceutical and biotechnological preparations for the diagnosis and treatment of proliferative human diseases, namely, cancer, fibrosis, inflammation, senescence, and diseases of aging; pharmaceutical and biotechnological preparations for the diagnosis and treatment of diseases, namely, including cancer, fibrosis, inflammation, senescence and diseases of aging; antibody drug conjugates (ADCs) for medical purposes; antibody drug conjugates (ADCs) for medical purposes for the diagnosis and treatment of human diseases; antibody drug conjugates (ADCs) for medical purposes for the diagnosis and treatment of proliferative human diseases; antibody drug conjugates (ADCs) for medical purposes for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging; N-myristoyltransferases (NMT) inhibitors in the nature of enzymes for medical purposes; N-myristoyltransferases (NMT) inhibitors in the nature of enzymes for medical purposes for the diagnosis and treatment of human diseases; Nmyristoyltransferases (NMT) inhibitors in the nature of enzymes for medical purposes for the diagnosis and treatment of proliferative human diseases; N-myristoyltransferases (NMT) inhibitors in the nature of enzymes for medical purposes for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging